U.S.-based PCI Pharma Services, a pharmaceutical development services provider, plans to invest $20 million to back its biologic medicines and upgraded injectable delivery forms.
The company will add extended biotechnology clinical and commercial packaging and release testing capability at its Center of Excellence in Philadelphia.
In addition, PCI will add extended Cold Chain capacity at several international locations to further back the company’s existing Biotech infrastructure.
PCI Pharma said that the infusions show its commitment to deliver lifesaving medicines to patients around the world.